Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Sinomab Bioscience Limited currently manages 2 pending office actions. These matters are concentrated under 1 distinct examiner, indicating a highly centralized prosecution focus for the portfolio. FAUST, AMBER KATHLEEN serves as the busiest examiner for the company. This individual is responsible for 2 pending office actions, representing the entirety of the current workload.
This concentration suggests that the company's legal strategy is currently funnelled through 1 single point of contact at the patent office. For practitioners, this means that the success of the portfolio is heavily dependent on the specific examination style and preferences of this 1 examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 2 | 60.6% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18578300 | METHODS OF TREATING NEUROLOGICAL DISEASES | FAUST, AMBER KATHLEEN | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — | §102§103 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18578300 | METHODS OF TREATING NEUROLOGICAL DISEASES | FAUST, AMBER KATHLEEN | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial